Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Bosutinib in Healthy Subjects
NCT02192294Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bosutinib in chronic myeloid leukemia (CML), sponsored by Pfizer. Primary endpoint: Area under the Concentration-Time Curve at 96 hours. Started Aug 2014; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02192294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02192294.